FN1 and inflammatory bowel disease: While in vivo targeting of fibronectin extra-domain A is well-characterized for molecular imaging and drug delivery in various autoimmune diseases including IBD [19], the previously identified D domain of tenascin C is largely unexplored for gastrointestinal diseases.